SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

This is a multicenter Phase II/III study evaluating the efficacy and safety of SCTB41 combined with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment in patients with driver-negative locally advanced or metastatic non-small cell lung cancer (NSCLC). The Phase II portion is an open-label safety run-in study enrolling approximately 30-60 patients to evaluate the safety and tolerability of SCTB41 plus chemotherapy. Following confirmation of acceptable safety and preliminary efficacy, the study will proceed to the Phase III portion. The Phase III portion is a ra

Trial Details

NCT ID

NCT07662395

Phase

PHASE2 / PHASE3

Sponsor

Sinocelltech Ltd.

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

SCTB41
Tislelizumab
Paclitaxel
Nab-paclitaxel
Carboplatin
Cisplatin

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Voluntary written informed consent (ICF) signed prior to screening.
Age ≥18 years, male or female.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Expected survival ≥3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →